The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis
Open accessAbstract
OBJECTIVES: We sought to evaluate the association between obesity and response to anti-tumor necrosis factor-α (TNF) agents, through a systematic review and meta-analysis. METHODS: Through a systematic search through January 24, 2017, we identified randomized controlled trials (RCTs) or observational studies in adults with select immune-mediated inflammatory diseases-inflammatory bowel diseases (IBD), rheumatoid arthritis (RA), spondyloarthropathies (SpA), psoriasis and psoriatic arthritis (PsA)-treated with anti-TNF agents, and reporting outcomes, stratified by body mass index (BMI) categories or weight. Primary outcome was failure to achieve clinical remission or response or treatment modification. We performed random effects meta-analysis and estimated odds ratios (OR) and 95% confidence interval (CI). RESULTS: Based on 54 cohorts including 19,372 patients (23% obese), patients with obesity had 60% higher odds of failing therapy (OR,1.60; 95% CI,1.39-1.83;I2 = 71%). Dose-response relationship was observed (obese vs. normal BMI: OR,1.87 [1.39-2.52]; overweight vs. normal BMI: OR,1.38 [1.11-1.74],p = 0.11); a 1kg/m2 increase in BMI was associated with 6.5% higher odds of failure (OR,1.065 [1.043-1.087]). These effects were observed across patients with rheumatic diseases, but not observed in patients with IBD. Effect was consistent based on dosing regimen/route, study design, exposure definition, and outcome measures. Less than 10% eligible RCTs reported outcomes stratified by BMI. CONCLUSIONS: Obesity is an under-reported predictor of inferior response to anti-TNF agents in patients with select immune-mediated inflammatory diseases. A thorough evaluation of obesity as an effect modifier in clinical trials is warranted, and intentional weight loss may serve as adjunctive treatment in patients with obesity failing anti-TNF therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, E. C., Biryukov, S., Abbafati, C., Abera, S. F., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60460-8 · Cited by 11,952
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Assessing Bias in Studies of Prognostic Factors
Hayden, J. A., van der Windt, D. A., Cartwright, J. L., Côté, P., & Bombardier, C. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-4-201302190-00009 · Cited by 3,287
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J. F., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rachmilewitz, D., Lichtiger, S., D'Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,143
Self-citation2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39480 · Cited by 2,777
Self-citationInflammatory links between obesity and metabolic disease
Lumeng, C. N., & Saltiel, A. R. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57132 · Cited by 2,319
Adipose tissue as an endocrine organ
Galic, S., Oakhill, J. S., & Steinberg, G. R. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.08.018 · Cited by 1,562
Sieper, J., & Poddubnyy, D. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31591-4 · Cited by 1,333
Sandborn, W. J., van Assche, G., Reinisch, W., Colombel, J., D’Haens, G., Wolf, D. C., Kron, M., Tighe, M. B., Lazar, A., & Thakkar, R. B. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.10.032 · Cited by 1,269
Self-citationThe economic burden of obesity worldwide: a systematic review of the direct costs of obesity
Withrow, D., & Alter, D. A. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00712.x · Cited by 1,083
Reinisch, W., Sandborn, W. J., Hommes, D. W., D'Haens, G., Hanauer, S., Schreiber, S., Panaccione, R., Fedorak, R. N., Tighe, M. B., Huang, B., et al. (2011) · Gut · doi:10.1136/gut.2010.221127 · Cited by 892
Self-citationClinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531280-000000000-00000 · Cited by 725
Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
Sandborn, W. J., Rutgeerts, P., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Lu, J., Horgan, K., Rachmilewitz, D., Hanauer, S. B., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.061 · Cited by 473
Self-citationObesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes
Singh, S., Dulai, P. S., Zarrinpar, A., Ramamoorthy, S., & Sandborn, W. J. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.181 · Cited by 452
Self-citationWarren, R. B., Smith, C. H., Yiu, Z. Z. N., Ashcroft, D. M., Barker, J. N. W. N., Burden, A. D., Lunt, M., McElhone, K., Ormerod, A. D., Owen, C., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.208 · Cited by 393
Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease
Nielsen, O. H., & Ainsworth, M. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmct1209614 · Cited by 334
Fat-wrapping in Crohn's disease: Pathological basis and relevance to surgical practice
Sheehan, A. L., Warren, B. F., Gear, M. W. L., & Shepherd, N. A. (1992) · Journal of British Surgery · doi:10.1002/bjs.1800790934 · Cited by 274
Peyrin-Biroulet, L., Gonzalez, F., Dubuquoy, L., Rousseaux, C., Dubuquoy, C., Decourcelle, C., Saudemont, A., Tachon, M., Béclin, E., Odou, M.-F., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300370 · Cited by 274
Menter, A., Papp, K. A., Gooderham, M., Pariser, D. M., Augustin, M., Kerdel, F. A., Fakharzadeh, S., Goyal, K., Calabro, S., Langholff, W., et al. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13611 · Cited by 244
Di Minno, M. N. D., Peluso, R., Iervolino, S., Russolillo, A., Lupoli, R., Scarpa, R., Di Minno, M. N. D., Russolillo, A., Di Minno, A., Tarantino, G., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202812 · Cited by 242
Qin, B., Yang, M., Fu, H., Ma, N., Wei, T., Tang, Q., Hu, Z., Liang, Y., Yang, Z., & Zhong, R. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0601-x · Cited by 239
Impact of Body Mass Index and Obesity on Clinical Response to Systemic Treatment for Psoriasis
Naldi, L., Addis, A., Chimenti, S., Giannetti, A., Picardo, M., Tomino, C., Maccarone, M., Chatenoud, L., Bertuccio, P., Caggese, E., et al. (2008) · Dermatology · doi:10.1159/000156599 · Cited by 226
Liu, Y., Hazlewood, G. S., Kaplan, G. G., Eksteen, B., & Barnabe, C. (2017) · Arthritis Care & Research · doi:10.1002/acr.22932 · Cited by 225
Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease
(2013) · New England Journal of Medicine · doi:10.1056/nejmc1312800 · Cited by 214
Gremese, E., Carletto, A., Padovan, M., Atzeni, F., Raffeiner, B., Giardina, A. R., Favalli, E. G., Erre, G. L., Gorla, R., Galeazzi, M., et al. (2013) · Arthritis Care & Research · doi:10.1002/acr.21768 · Cited by 208
Eder, L., Thavaneswaran, A., Chandran, V., Cook, R. J., & Gladman, D. D. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204448 · Cited by 204
Body mass index and clinical response to infliximab in rheumatoid arthritis
Klaasen, R., Wijbrandts, C. A., Gerlag, D. M., & Tak, P. P. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30136 · Cited by 188
Obesity and the prediction of minimal disease activity: A prospective study in psoriatic arthritis
di Minno, M. N. D., Peluso, R., Iervolino, S., Lupoli, R., Russolillo, A., Scarpa, R., & di Minno, G. (2013) · Arthritis Care & Research · doi:10.1002/acr.21711 · Cited by 187
Kerschbaumer, A., Smolen, J. S., Dougados, M., de Wit, M., Primdahl, J., McInnes, I., van der Heijde, D., Baraliakos, X., Falzon, L., & Gossec, L. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217163 · Cited by 177
Harper, J. W., D, M. N. S. M., & Zisman, T. L. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e31829cf401 · Cited by 175
Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial
Sandborn, W. J., Schreiber, S., Feagan, B. G., Rutgeerts, P., Younes, Z. H., Bloomfield, R., Coteur, G., Guzman, J. P., & D'Haens, G. R. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.04.031 · Cited by 175
Self-citationSandberg, M. E. C., Bengtsson, C., Källberg, H., Wesley, A., Klareskog, L., Alfredsson, L., & Saevarsdottir, S. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-205094 · Cited by 168
Measures of Obesity and Risk of Crohnʼs Disease and Ulcerative Colitis
Khalili, H., Ananthakrishnan, A. N., Konijeti, G. G., Higuchi, L. M., Fuchs, C. S., Richter, J. M., & Chan, A. T. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000283 · Cited by 166
Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis
Menter, A., Gordon, K. B., Leonardi, C. L., Gu, Y., & Goldblum, O. M. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.09.040 · Cited by 164
Højgaard, P., Glintborg, B., Kristensen, L. E., Guðbjörnsson, B., Löve, Þ. J., & Dreyer, L. (2016) · Rheumatology · doi:10.1093/rheumatology/kew326 · Cited by 153
Obesity and psoriasis: From the Medical Board of the National Psoriasis Foundation
Bremmer, S. F., Voorhees, A. S. V., Hsu, S., Korman, N. J., Lebwohl, M., Young, M. S., Bebo, B. F., & Blauvelt, A. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.09.053 · Cited by 152
Gottlieb, A. B., Langley, R. G. B., Strober, B. E., Papp, K. A., Klekotka, P. A., Creamer, K., Thompson, E. H. Z., Hooper, M., & Kricorian, G. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.11015.x · Cited by 143
Upala, S., & Sanguankeo, A. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.64 · Cited by 134
Body weight, gender and response to TNF- blockers in axial spondyloarthritis
Gremese, E., Bernardi, S., Bonazza, S., Nowik, M., Peluso, G., Massara, A., Tolusso, B., Messuti, L., Miceli, M. C., Zoli, A., et al. (2014) · Lara D. Veeken · doi:10.1093/rheumatology/ket433 · Cited by 125
Kobayashi, T., Suzuki, Y., Motoya, S., Hirai, F., Ogata, H., Ito, H., Sato, N., Ozaki, K., Watanabe, M., & Hibi∥, T. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1102-z · Cited by 118
Ramiro, S., Smolen, J. S., Landewé, R., van der Heijde, D. M. F. M., Dougados, M., Emery, P., de Wit, M. P. T., Cutolo, M., Oliver, S. M., & Gossec, L. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208466 · Cited by 110
Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients
Bultman, E., de Haar, C. G., van Liere-Baron, A., Verhoog, H. J., West, R. L., Kuipers, E. J., Zelinková, Z., & van der Woude, C. J. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04946.x · Cited by 107
Bagel, J., Lynde, C. W., Tyring, S. K., Kricorian, G., Shi, Y., & Klekotka, P. A. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2011.07.034 · Cited by 106
Body mass index influences the response to infliximab in ankylosing spondylitis
Ottaviani, S., Allanore, Y., Tubach, F., Forien, M., Gardette, A., Pasquet, B., Palazzo, É., Meunier, M., Hayem, G., Job-Deslandre, C., et al. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3841 · Cited by 103
Weinblatt, M. E., Bingham, C. O., Mendelsohn, A. M., Kim, L., Mack, M., Lu, J., Baker, D., & Westhovens, R. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201411 · Cited by 103
Cai, L., Gu, J., Zheng, J., Zheng, M., Wang, G., Xi, L., Hao, F., Liu, X. ‐., Sun, Q. ‐., Wang, Y., et al. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13746 · Cited by 102
Anti-TNF-α Agents Are Less Effective for the Treatment of Rheumatoid Arthritis in Current Smokers
Abhishek, A., Butt, S. A., Gadsby, K., Zhang, W., & Deighton, C. (2009) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e3181ca4a2a · Cited by 97
Impact of Bariatric Surgery on Patients With Rheumatoid Arthritis
Sparks, J. A., Halperin, F., Karlson, J. C., Karlson, E. W., & Bermas, B. L. (2015) · Arthritis Care & Research · doi:10.1002/acr.22629 · Cited by 93
Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis
Mease, P. J., Sieper, J., den Bosch, F. E. V., Rahman, P., Karunaratne, P. M., & Pangan, A. L. (2014) · Arthritis & Rheumatology · doi:10.1002/art.39008 · Cited by 87
Zweegers, J., van den Reek, J. M. P. A., van de Kerkhof, P. C. M., Otero, M. E., Kuijpers, A. L. A., Koetsier, M. I. A., Arnold, W. P., Berends, M. A. M., Parren, L. J. M. T., Ossenkoppele, P. M., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14552 · Cited by 81
Ogdie, A., Schwartzman, S., Eder, L., Maharaj, A. B., Zisman, D., Raychaudhuri, S. P., Reddy, S. M., & Husni, M. E. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.140882 · Cited by 75
Costa, L., Caso, F., Ramonda, R., PUENTE, A. D., Cantarini, L., Darda, M. A., Caso, P., Lorenzin, M., Fiocco, U., Punzi, L., et al. (2014) · Immunologic Research · doi:10.1007/s12026-014-8595-z · Cited by 75
Bhalme, M., Sharma, A., Keld, R. R., et al. (2013) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32835d1f15 · Cited by 74
Lupoli, R., Pizzicato, P., Scalera, A., Ambrosino, P., Amato, M., Peluso, R., & Minno, M. N. D. D. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-1194-8 · Cited by 71
Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis
Lernia, V. G. D., Tasin, L., Pellicano, R., Zumiani, G., & Albertini, G. (2011) · Journal of Dermatological Treatment · doi:10.3109/09546634.2011.593489 · Cited by 53
−174G/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-&agr; blockers
di Renzo, L., Bianchi, A., Saraceno, R., Calabrese, V., Cornelius, C., Iacopino, L., Chimenti, S., & de Lorenzo, A. (2012) · Pharmacogenetics & Genomics · doi:10.1097/fpc.0b013e32834e5e7b · Cited by 52
Cassano, N., Loconsole, F., Galluccio, A. G., Miracapillo, A., Pezza, M., & Vena, G. A. (2006) · International Journal of Immunopathology and Pharmacology · doi:10.1177/205873920601900123 · Cited by 49
Mostafa, N. M., Nader, A. M., Noertersheuser, P. A., Okun, M. M., & Awni, W. M. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13884 · Cited by 48
Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease
Singh, S., & Pardi, D. S. (2014) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2014.05.008 · Cited by 37
Self-citationPrussick, R. B., Unnebrink, K., & Valdecantos, W. C. (2015) · PubMed · Cited by 36
Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy
Iannone, F., Fanizzi, R., Scioscia, C., Anelli, M. G., & Lapadula, G. (2012) · Scandinavian Journal of Rheumatology · doi:10.3109/03009742.2012.715186 · Cited by 33
Choi, C. H., Song, I. D., Kim, Y.-H., Koo, J. S., Kim, Y. S., Kim, J. S., Kim, N., Kim, E. S., Kim, J. H., Kim, J. W., et al. (2016) · Yonsei Medical Journal · doi:10.3349/ymj.2016.57.6.1376 · Cited by 31
Cited by
Kennedy, N. A., Heap, G. A., Green, H. D., Hamilton, B., Bewshea, C., Walker, G. J., Thomas, A., Nice, R., Perry, M. H., Bouri, S., et al. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30012-3 · Cited by 691
Self-citationCortellini, A., Bersanelli, M., Buti, S., Cannita, K., Santini, D., Perrone, F., Giusti, R., Tiseo, M., Michiara, M., Di Marino, P., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0527-y · Cited by 413
Mazhar, F., Battini, V., Gringeri, M., Pozzi, M., Mosini, G., Marran, A. M. N., Akram, S., van Manen, R. P., Radice, S., Clementi, E., et al. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1948529 · Cited by 67
Metadata
- Authors
- Singh, S., Facciorusso, A., Singh, A. G., Casteele, N. V., Zarrinpar, A., Prokop, L. J., Grunvald, E. L., Curtis, J. R., & Sandborn, W. J.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-05-17
- Volume
- 13
- Issue
- 5
- Pages
- e0195123
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2804607344
- Cited by
- 293
- References
- 68
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.